From a trial design perspective, we’ve tried to make these trials as familiar to stakeholders – regulators, prescribers, payors – as possible. What’s remarkable here are the qualities of the drug that we’re developing, MM120, a pharmaceutical formulation of LSD; we don’t need to do anything inconsistent with the history of psychiatric clinical trials beyond that.